Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | MAX | P61244 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007677 | 0.82 | MYC (0.46) | MYCMAXMAPTKDM4ERECQL | |
| SCHEMBL9007679 | 0.82 | MYC (0.46) | MYCMAXMAPTKDM4ERECQL | |
| SCHEMBL20157040 | 0.76 | MYC (0.41) | MYCMAXALOX15PTGS2 | |
| SCHEMBL13848482 | 0.72 | MAPT (0.57) | MAPTKDM4ERECQLPOLBMEN1 | |
| SCHEMBL3084677 | 0.68 | ALDH1A1 (0.38) | MYCMAXALDH1A1SMN1; SMN2 | |
| SCHEMBL12961158 | 0.67 | MYC (0.70) | MYCMAXTDP1ALOX15PTGS2 | |
| SCHEMBL8176930 | 0.64 | MYC (1.00) | MYCMAXMAPTMEN1ALDH1A1 | |
| SCHEMBL18102966 | 0.64 | MYC (1.00) | MYCMAXMAPTMEN1ALDH1A1 | |
| SCHEMBL10447337 | 0.64 | MYC (0.41) | MYCMAXALOX15PTGS2 | |
| SCHEMBL10447338 | 0.64 | MYC (0.41) | MYCMAXALOX15PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| WO-2013024447-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAX | MYC 397/4885MAX 4172/4885MAPT 2828/4885 |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAK1 | MYC 131/4885MAX 4562/4885MAPT 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.